Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib

Leukemia Research

Volumn 37, Issue 6, 2013, Pages 641-646

  Fernández de Larrea, Carlos ^a,b   Martín Antonio, Beatriz ^a,b   Cibeira, Maria Teresa ^a,b   Navarro, Alfons ^b   Tovar, Natalia ^a,b   Díaz, Tania ^b   Rosiñol, Laura ^a,b   Monzó, Mariano ^b   Urbano Ispizua, Alvaro ^a,b   Bladé, Joan ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bortezomib; DNA; Methylation; Myeloma; NFKB1; Prognosis

Indexed keywords

BORTEZOMIB; DNA;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW CELL; CANCER RECURRENCE; CPG ISLAND; DNA ISOLATION; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NFKB1 GENE; OVERALL SURVIVAL; PLASMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; SUBSTRATE SPECIFICITY;

EID: 84877029737     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.01.013     Document Type: Article

References (39)

1. Blade J., Rosinol L. Advances in therapy of multiple myeloma. Curr Opin Oncol 2008, 20:697-704.
2. Chauhan D., Hideshima T., Mitsiades C., Richardson P., Anderson K.C. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005, 4:686-692.
3. Hideshima T., Mitsiades C., Akiyama M., Hayashi T., Chauhan D., Richardson P., et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003, 101:1530-1534.
4. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
5. Rosiñol L., Oriol A., Teruel A.I., et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012, 120:1589-1596.
6. Cavo M., Tacchetti P., Patriarca F., Petrucci M.T., Pantani L., Galli M., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376:2075-2085.
7. Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
8. Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111:2521-2526.
9. Ludwig H., Bolejack V., Crowley J., Blade J., Miguel J.S., Kyle R.A., et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010, 28:1599-1605.
10. Kumar S.K., Lee J.H., Lahuerta J.J., Morgan G., Richardson P.G., Crowley J., et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012, 26:149-157.
11. Avet-Loiseau H., Leleu X., Roussel M., Moreau P., Guerin-Charbonnel C., Caillot D., et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010, 28:4630-4634.
12. Mateos M.V., Hernandez J.M., Hernandez M.T., Gutierrez N.C., Palomera L., Fuertes M., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008, 93:560-565.
13. Vangsted A., Klausen T.W., Vogel U. Genetic variations in multiple myeloma II: association with effect of treatment. Eur J Haematol 2012, 88:93-117.
14. Decaux O., Lode L., Magrangeas F., Charbonnel C., Gouraud W., Jezequel P., et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 2008, 26:4798-4805.
15. Gutierrez N.C., Sarasquete M.E., Misiewicz-Krzeminska I., Delgado M., De Las Rivas J., Ticona F.V., et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010, 24:629-637.
16. Walker B.A., Wardell C.P., Chiecchio L., Smith E.M., Boyd K.D., Neri A., et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011, 117:553-562.
17. Proposed guidelines for protocol studies. II Plasma cell myeloma. Prepared by a Committee of the Chronic Leukemia - Myeloma Task Force, National Cancer Institute. Cancer Chemother Rep 1968, 3(1):17-39.
18. Blade J., Samson D., Reece D., Apperley J., Bjorkstrand B., Gahrton G., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
19. Anderson K.C., Kyle R.A., Rajkumar S.V., Stewart A.K., Weber D., Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008, 22:231-239.
20. Saeed A., Sharov V., White J., Li J., Liang W., Bhagabati N., et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34:375-378.
21. R: A Language and Environment for Statistical Computing. In: Computing RFfS, editor. Vienna Austria; 2008. http://www.r-project.org/.
22. Heuck C., Mehta J., Tariman J., Pulliam N., Yu Y., Bhagat T., et al. Epigenomic profiling of multiple myeloma shows widespread stage specific alterations in DNA methylation that occur early during myelomagenesis. Blood 2010, 116:784. Abstract ASH meeting.
23. Eden A., Gaudet F., Waghmare A., Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
24. Salhia B., Baker A., Ahmann G., Auclair D., Fonseca R., Carpten J. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res 2010, 70:6934-6944.
25. Bollati V., Fabris S., Pegoraro V., Ronchetti D., Mosca L., Deliliers G.L., et al. Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis 2009, 30:1330-1335.
26. de Carvalho F., Colleoni G.W., Almeida M.S., Carvalho A.L., Vettore A.L. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer 2009, 125:1985-1991.
27. Galm O., Yoshikawa H., Esteller M., Osieka R., Herman J.G. SOCS-1a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003, 101:2784-2788.
28. Seidl S., Ackermann J., Kaufmann H., Keck A., Nosslinger T., Zielinski C.C., et al. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004, 100:2598-2606.
29. Mateos M.V., Garcia-Sanz R., Lopez-Perez R., Moro M.J., Ocio E., Hernandez J., et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002, 118:1034-1040.
30. Takada S., Morita K., Hayashi K., Matsushima T., Sawamura M., Murakami H., et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur J Haematol 2005, 75:505-510.
31. Braggio E., Maiolino A., Gouveia M.E., Magalhaes R., Souto Filho J.T., Garnica M., et al. Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol 2010, 91:87-96.
32. Alsayed Y., Ngo H., Runnels J., Leleu X., Singha U.K., Pitsillides C.M., et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007, 109:2708-2717.
33. Vande Broek I., Leleu X., Schots R., Facon T., Vanderkerken K., Van Camp B., et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 2006, 91:200-206.
34. Oliveira A.M., Maria D.A., Metzger M., Linardi C., Giorgi R.R., Moura F., et al. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res 2009, 33:970-973.
35. Azab A.K., Runnels J.M., Pitsillides C., Moreau A.S., Azab F., Leleu X., et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113:4341-4351.
36. De Bruyne E., Bos T.J., Asosingh K., Vande Broek I., Menu E., Van Valckenborgh E., et al. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res 2008, 14:2918-2926.
37. Hideshima T., Ikeda H., Chauhan D., Okawa Y., Raje N., Podar K., et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114:1046-1052.
38. Nojima M., Maruyama R., Yasui H., Suzuki H., Maruyama Y., Tarasawa I., et al. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res 2009, 15:4356-4364.
39. Wong K.Y., Yim R.L., So C.C., Jin D.Y., Liang R., Chim C.S. Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood 2011, 118:5901-5904.